Abstract: The present specification provides a method of calculating a diagnostic score for prostate cancer by combining at least two values. The method comprises preparing a sample, obtaining a first value, obtaining a second value, and calculating a diagnostic score. The sample is a urine sample from a subject, and the first value corresponds to an amount of a hsa-miR-3659 or hsa-miR-3679-5p derived from extracellular vesicles in the sample, and the second value corresponds to a miRNA derived from the extracellular vesicles in the sample. Both the first and second values include information on whether the subject has developed prostate cancer, and the second value corresponds to a normalization factor specialized for the first value. The diagnostic score for prostate cancer calculated according to the method is characterized by being capable of diagnosing prostate cancer. The present specification provides a use of the diagnostic score for prostate cancer.

Abstract: The present specification provides a method of calculating a diagnostic score for prostate cancer by combining at least two values. The method comprises preparing a sample, obtaining a first value, obtaining a second value, and calculating a diagnostic score. The sample is a urine sample from a subject, and the first value corresponds to an amount of a hsa-miR-3659 or hsa-miR-3679-5p derived from extracellular vesicles in the sample, and the second value corresponds to a miRNA derived from the extracellular vesicles in the sample. Both the first and second values include information on whether the subject has developed prostate cancer, and the second value corresponds to a normalization factor specialized for the first value. The diagnostic score for prostate cancer calculated according to the method is characterized by being capable of diagnosing prostate cancer. The present specification provides a use of the diagnostic score for prostate cancer.

Abstract: The present invention provides a novel use of hsvI-miR-H18 or hsv2-miR-H9-5p, which is microRNA, for the diagnosis of prostate cancer. According to hsvI-miR-H18 or hsv2-miR-H9-5p of the present invention, it is possible to accurately diagnose even a subject in the PSA gray zone in which accurate diagnosis though PSA is difficult. The present invention can be applied to various biological samples, and exerts accurate diagnostic ability even when a supernatant of the solution excluding, particularly, cell-derived materials is used, and thus a diagnostic procedure is simple and convenient. According to the present invention, the prostate cancer can be accurately and promptly diagnosed at low costs.